Background In evidence‐based guidelines published in 2000, topiramate was a third‐tier
migraine preventive with no scientific evidence of efficacy; recommendation for its use …

In the past twenty-one years, 17 new antiepileptic drugs have been approved for use in the
United States and/or Europe. These drugs are clobazam, ezogabine (retigabine) …

Abstract Since 2010, the Food and Drug Administration has approved the use of four new
anti-epilepsy drugs (AEDs) for the treatment of epilepsy in the USA: clobazam (Onfi) …

Poor adherence to anti-seizure medications (ASMs) is associated with breakthrough
seizures and potentially increased toxicity in patients with epilepsy. Extended-release (ER) …

Introduction: Migraine is a frequent, disabling primary headache disorder, whose
pathomechanism is not yet fully understood. Prophylactic treatment is advisable for …

Following a decision to require label warnings for concurrent use of opioids and
benzodiazepines and increased risk of respiratory depression and death, the US Food and …

Modified-release or extended-release (XR) formulations are used to decrease the frequency
of dosing for drugs with rapid elimination, to improve convenience and adherence. Use of a …

Objective For extended-release drugs with multi-compartment kinetics, such as topiramate,
effective half-life (t 1/2eff) may be a more clinically relevant parameter than elimination half …

Introduction Generic products of antiepileptic drugs (AEDs) are currently a controversial
topic as neurologists and patients are reluctant to switch from brand products to generics …

Objective To evaluate the efficacy and safety of USL 255, Qudexy™ XR (topiramate)
extended‐release capsules, as an adjunctive treatment for refractory partial‐onset seizures …